TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$135 Million

Foghorn Therapeutics

Initial Public Offering

Bookrunner, October 2020

Foghorn Therapeutics

Foghorn Therapeutics Inc. is a developmental-stage precision medicine company focused on pioneering the discovery and development of small molecule therapies targeting genetically determined dependencies in the chromatin regulatory system. The Company has developed its proprietary Gene Traffic Control platform which allows the Company to identify and validate drug targets within the chromatin regulatory system. With an initial focus in oncology, the Company has utilized its Gene Traffic Control platform to generate a deep pipeline of novel product candidates consisting of enzyme inhibitors, protein degraders and protein-protein interaction disruptors that address a broad array of cancers. Lead product candidates, FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, are being developed to treat hematologic cancers and solid tumors. The Company has several preclinical programs underway including selective BRM and ARID1B modulators, as well as programs beyond BAF.